Metsera is also joining its metabolic medicines peers who are developing oral GLP-1 drugs. The biotech’s candidate is MET-224o, an ultra-long acting GLP-1 receptor agonist made with technology ...

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. And the company is ready to scale up. Published: Feb. 25, 2025 at 1:42 p.m. ET. Share.